| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
IX 207-887 targets the release of interleukin-1 (IL-1), a pro-inflammatory cytokine that plays a central role in the pathogenesis of inflammatory diseases, including rheumatoid arthritis. By inhibiting IL-1 release from monocytes and macrophages, the compound suppresses inflammatory responses and reduces tissue damage.
|
|---|---|
| ln Vitro |
IX 207-887 is a novel anti-arthritic medication that prevents mouse peritoneal macrophages and human monocytes from releasing interleukin-1 (IL-1). While IL-1 levels in homogenates or lysates were either unchanged or only marginally decreased, IX 207-887 dramatically decreased bioactive and immunoreactive IL-1 in the culture medium in every system that was tested. IX 207-887 did not significantly reduce thymocyte proliferation induced by IL-1 or IL-2, nor did it affect human monocyte adhesion. IX 207-887 did not exhibit any IL-1 antagonistic activity in chondrocyte assays [1].
In vitro, IX 207-887 is a novel antiarthritic agent that inhibits the release of IL-1 from human monocytes and mouse peritoneal macrophages. While homogenate or lysate IL-1 levels show little or no change, IX 207-887 significantly reduces bioactive and immunoreactive IL-1 in the culture medium of each test system. |
| ln Vivo |
In vivo, IX 207-887 has been studied as an antiarthritic agent. Its ability to inhibit IL-1 release suggests potential for the treatment of inflammatory diseases such as rheumatoid arthritis. Further in vivo studies are needed to fully characterize its efficacy and safety.
|
| Enzyme Assay |
In vitro enzyme assays are not typically performed for IX 207-887, as its mechanism of action is based on inhibition of IL-1 release rather than direct enzyme inhibition. Instead, its activity is assessed by measuring IL-1 levels in cell culture supernatants using ELISA or bioassays.
|
| Cell Assay |
In vitro cellular assays for IX 207-887 are performed using human monocytes or mouse peritoneal macrophages. Cells are stimulated (e.g., with LPS) to induce IL-1 production and release, and then treated with the compound. IL-1 levels in the culture medium are measured by ELISA. The compound's effect on cell adherence and proliferation is also assessed to evaluate its specificity.
|
| Animal Protocol |
In vivo animal experiments for IX 207-887 are conducted in animal models of arthritis or other inflammatory diseases. A typical protocol involves administration of the compound via oral or intraperitoneal routes to animals with induced arthritis, followed by assessment of disease severity, joint inflammation, and inflammatory markers in serum or tissues.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of IX 207-887 have not been systematically characterized. The compound has a molecular weight of 284.33 and is supplied as a research compound. Further PK studies are needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for IX 207-887 are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
IX 207-887 is a novel antiarthritic agent that inhibits the release of interleukin-1 (IL-1) from human monocytes and mouse peritoneal macrophages. It suppresses inflammatory responses by reducing IL-1 secretion. This product is for research use only.
|
| Molecular Formula |
C16H12O3S
|
|---|---|
| Molecular Weight |
284.32968
|
| Exact Mass |
284.051
|
| CAS # |
98320-39-9
|
| PubChem CID |
6509858
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.722
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
455
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC2=CC=CC=C2/C(=C/C(=O)O)/C3=C1SC=C3
|
| InChi Key |
XIKRQPKFOKKGGW-LCYFTJDESA-N
|
| InChi Code |
InChI=1S/C16H12O3S/c1-19-14-8-10-4-2-3-5-11(10)13(9-15(17)18)12-6-7-20-16(12)14/h2-9H,1H3,(H,17,18)/b13-9-
|
| Chemical Name |
(2Z)-2-(8-methoxy-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,8,10,12-hexaen-2-ylidene)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~351.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5170 mL | 17.5852 mL | 35.1704 mL | |
| 5 mM | 0.7034 mL | 3.5170 mL | 7.0341 mL | |
| 10 mM | 0.3517 mL | 1.7585 mL | 3.5170 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
